Nofal Eman, Elkot Reham, Nofal Ahmad, Eldesoky Fatma, Shehata Shymaa, Sami Maha
Department of Dermatology and Venereology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
J Cosmet Dermatol. 2018 Dec;17(6):1000-1007. doi: 10.1111/jocd.12478. Epub 2018 Jan 3.
Management of periorbital hyperpigmentation (POH) is still a therapeutic challenge. Although different therapeutic modalities are available, the outcomes of most of them are unsatisfactory.
To investigate and compare the efficacy and safety of two new modalities in the treatment of POH; the platelet rich plasma (PRP) and the carboxytherapy.
The study included 30 patients with POH. Every patient was subjected to seven intradermal injections of PRP on the left periorbital area with 2 week intervals between sessions and carboxytherapy on the right area with 1 week interval apart. Assessments were done by investigators' assessment, visual analogue scale by both patients and doctors, and patients' satisfaction. Side effects were reported.
All patients completed the sessions in the carboxy-treated side. In the PRP-treated side, 10 patients refused to complete all sessions because of intolerable side effects. Significant improvement in POH was achieved in both sides (P ≤ .0001). The improvement was comparable with no statistically significant difference between both modalities. Side effects in the carboxy treated side were mild and well tolerated by all patients while they were relatively severe, and persisted for days after sessions in the PRP-treated side.
Both PRP and carboxytherapy are relatively effective and their efficacy is comparable in treatment of POH. Carboxtherapy is simple and slightly more effective modality and well tolerated than PRP. We believe that both modalities are promising but not the ideal solutions of the POH problem which is caused by multifactorial etiology.
眶周色素沉着(POH)的治疗仍然是一项治疗挑战。尽管有多种治疗方式可供选择,但大多数治疗效果并不理想。
研究并比较两种新的治疗方式在治疗POH中的疗效和安全性;富血小板血浆(PRP)和羧基疗法。
该研究纳入了30例POH患者。每位患者在左眶周区域接受7次皮内注射PRP,每次注射间隔2周,在右眶周区域接受羧基疗法,每次治疗间隔1周。通过研究者评估、患者和医生的视觉模拟评分以及患者满意度进行评估。记录副作用情况。
所有患者均完成了羧基治疗侧的疗程。在PRP治疗侧,10例患者因无法耐受的副作用而拒绝完成所有疗程。两侧POH均有显著改善(P≤0.0001)。两种治疗方式的改善效果相当,无统计学显著差异。羧基治疗侧的副作用轻微,所有患者均可耐受,而PRP治疗侧的副作用相对严重,治疗后持续数天。
PRP和羧基疗法在治疗POH方面均相对有效,且疗效相当。羧基疗法操作简单,比PRP稍有效,耐受性更好。我们认为这两种治疗方式都很有前景,但并非解决由多因素病因引起的POH问题的理想方案。